Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Biochemical Engineering >Inhibitors >Metabolism >P450 (e.g. CYP17) inhibitor >Avasimibe

Avasimibe

Avasimibe Structure
  • ₹13552.9 - ₹30667.23
  • Product name: Avasimibe
  • CAS: 166518-60-1
  • MF: C29H43NO4S
  • MW: 501.72
  • EINECS:1592732-453-0
  • MDL Number:MFCD00934956
  • Synonyms:Avasimibe, >=98%;2,6-diisopropylphenyl 2-(2,4,6-triisopropylphenyl)acetylsulfamate;[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester] sulfamic acid;PD 148515;avasimibe;n-(2,6-dipropan-2-ylphenoxy)sulfonyl-2-(2,4,6-tripropan-2-ylphenyl)acetamide;N-[(2,6-DIISOPROPYLPHENOXY)SULFONYL]-2-(2,4,6-TRIISOPROPYLPHENYL)ACETAMIDE;((2,4,6-TRIS(1-METHYLETHYL)PHENYL)ACETYL)SULFAMICACID2,6-BIS(1-METHYLETHYL)PHENYLESTER
2 prices
Selected condition:

Brand

  • Sigma-Aldrich(India)

Package

  • 5MG
  • 25MG
  • ManufacturerSigma-Aldrich(India)
  • Product numberPZ0190
  • Product descriptionAvasimibe ≥98% (HPLC)
  • Packaging25MG
  • Price₹30667.23
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberPZ0190
  • Product descriptionAvasimibe ≥98% (HPLC)
  • Packaging5MG
  • Price₹13552.9
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
Sigma-Aldrich(India) PZ0190 Avasimibe ≥98% (HPLC) 25MG ₹30667.23 2022-06-14 Buy
Sigma-Aldrich(India) PZ0190 Avasimibe ≥98% (HPLC) 5MG ₹13552.9 2022-06-14 Buy

Properties

Melting point :178-180° (Lee); mp 169.5-170.4° (Dozeman)
Density :1.072±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :DMSO: ≥40mg/mL
form :powder
pka :1.97±0.70(Predicted)
color :white to tan
InChIKey :PTQXTEKSNBVPQJ-UHFFFAOYSA-N

Safety Information

Symbol(GHS):
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:

Description

Acyl-Coenzyme A:cholesterol acyltransferases (ACAT1 and ACAT2) catalyze the formation of cholesterol esters from cholesterol and long chain fatty acyl-coenzyme A, and may play a role in the development of atherosclerosis. Avasimibe is an orally bioavailable inhibitor of ACAT (IC50s = 24 and 9.2 μM for ACAT1 and ACAT2, respectively). It reduces foam cell formation in human macrophages in vitro, enhancing free cholesterol efflux and inhibiting the uptake of modified LDL and dose-dependently reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models. Avasimibe inhibition of ACAT has been used to decrease amyloid β generation in models of Alzheimer’s disease.

Related product price